Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)

被引：0
|
作者：
Normanno, N. [1 ]
Rachiglio, A. M. [1 ]
Abate, R. Esposito [1 ]
Orlandi, A. [2 ]
Maiello, E. [3 ]
Maglietta, G. [4 ,5 ]
Damato, A. [3 ]
Maiello, M. R. [1 ]
Carotenuto, M. [1 ]
Calegari, M. A. [2 ]
Antonuzzo, L. [6 ]
Bordonaro, R. [7 ]
Zampino, M. G. [8 ]
Tamberi, S.
Lonardi, S. [9 ]
Avallone, A. [10 ]
Latiano, T. P. [3 ]
Tamburini, E. [11 ]
Barone, C. A. [2 ]
Pinto, C.
机构：
[1] Ist Nazl Tumori IRCCS Fondazione G Pascale, Translat Res Dept, Naples, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Dept, Rome, Italy
[3] Med Oncol, IRCCS Fdn Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[4] Azienda Osped Univ Parma, Clin & Epidemiol Res Unit, Parma, Italy
[5] IRCCS, Azienda Osped Arcispedale Santa Maria Nuov, Reggio Emilia, Italy
[6] AOUC, Med Oncol Dept, Florence, Italy
[7] Dept Oncol, Azienda Osped ARNAS Garibaldi, Catania, Italy
[8] Osped Santa Maria Croci, Med Oncol, Ravenna, Italy
[9] IRCCS, Dept Oncol, IOV Ist Oncol Veneto, Padua, Italy
[10] IRCCS Fdn G Pascale, Ist Nazl Tumori, Abdominal Oncol Dept, Naples, Italy
[11] Azienda Osped Cardinale Giovanni Panico, Med Oncol, Tricase, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.122
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111P
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [2] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
    Normanno, Nicola
    Rachiglio, Anna Maria
    Abate, Riziero Esposito
    Orlandi, Armando
    Maiello, Evaristo
    Maglietta, Giuseppe
    Damato, Angela
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Avallone, Antonio
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Barone, Carlo Antonio
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Rachiglio, Anna Maria
    Maglietta, Giuseppe
    Damato, Angela
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Tonini, Giuseppe
    Rosati, Gerardo
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Barone, Carlo
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC
    Pinto, Carmine
    Normanno, Nicola
    Orlandi, Armando
    Fenizia, Francesca
    Damato, Angela
    Maiello, Evaristo
    Tamburini, Emiliano
    Di Costanzo, Francesco
    Tonini, Giuseppe
    Bilancia, Domenico
    Corsi, Domenico
    Pisconti, Salvatore
    Ferrau, Francesco
    Gori, Stefania
    Daniele, Bruno
    Zaniboni, Alberto
    Parra, Hector Soto
    Frassinetti, Giovanni Luca
    Iaffaioli, Rosario Vincenzo
    Cassata, Antonio
    Zampino, Maria Giulia
    Repetto, Lazzaro
    Calegari, Maria Alessandra
    Barone, Carlo
    FUTURE ONCOLOGY, 2018, 14 (14) : 1339 - 1346
  • [5] Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI plus cetuximab until disease progression compared to FOLFIRI plus cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.
    Pinto, Carmine
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Bilancia, Domenico
    Corsi, Domenico C.
    Tamburini, Emiliano
    Pisconti, Salvatore
    Ferrau, Francesco
    Di Costanzo, Francesco
    Gori, Stefania
    Daniele, Bruno
    Tonini, Giuseppe
    Zaniboni, Alberto
    Soto-Parra, Hector
    Frassinetti, Giovanni Luca
    Iaffaioli, Rosario Vincenz
    Zampino, M. Giulia
    Repetto, Lazzaro
    Barone, Carlo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
    Cervantes, A.
    Macarulla, T.
    Martinelli, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Stroh, C.
    Nippgen, J.
    Baselga, J.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
    Pinto, Carmine
    Orlandi, Armando
    Normanno, Nicola
    Maiello, Evaristo
    Calegari, Maria A.
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria G.
    Pini, Sara
    Bergamo, Francesca
    Tonini, Giuseppe
    Avallone, Antonio
    Latiano, Tiziana P.
    Rosati, Gerardo
    Cogoni, Alessio Aligi
    Ballestrero, Alberto
    Zaniboni, Alberto
    Roselli, Mario
    Tamberi, Stefano
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1278 - 1287
  • [9] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [10] CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Bodoky, G.
    Kyung Roh, J.
    Folprecht, G.
    Park, Y. S.
    Van Laethem, J. L.
    Raoul, J. L.
    Ciardiello, F.
    Lebrun, P.
    Rougier, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 235
12345